Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

NCT05288205 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS P.G12C
Non-small Cell Lung Cancer
Colorectal Cancer
Pancreatic Ductal Carcinoma

Interventions

DRUG: JAB-21822
DRUG: JAB-3312

Sponsor

Allist Pharmaceuticals, Inc.